La cadena de opciones muestra datos clave de las opciones de acciones de Scilex Holding a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Scilex Holding..

Scilex Holding (NASDAQ:SCLX) Bolsa, Cadena de Opciones

SCILEX HOLDING CO

Scilex Holding

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Scilex Holding Co

Needham analyst Gil Blum reiterates I-MAB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) with a Buy and maintains $4 price target.

News

Price Target

Reiteration

Analyst Ratings

IMAB

Needham Reiterates Buy on I-MAB, Maintains $4 Price Target

HC Wainwright &amp; Co. analyst Andrew Fein maintains I-MAB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) with a Buy and lowers the price target from $8 to $7.

HC Wainwright & Co. Maintains Buy on I-MAB, Lowers Price Target to $7

Two prominent voices in crypto investing—Arthur Hayes and Dan Tapiero—are framing the latest wave of U.S. tariffs as a symptom of deeper structural issues in the <a href="https://www.benzinga.com/markets/equities/25/04/44631713/tariffs-will-provide-great-buying-opportunity-in-long-term-investors-must-first-cross-stagflatio">global financial system</a>, arguing that Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) may stand to benefit from the resulting distortions.
The comments come amid heightened trade tensions following sweeping tariff announcements by the U.S., intended to counter foreign exchange manipulation, persistent trade deficits, and <a href="https://www.benzinga.com/markets/25/04/44621408/market-access-has-a-price-trump-unveils-list-of-tariffs-countries-targeted">sluggish domestic growth</a>.
But for Hayes, co-founder of BitMEX, and Tapiero, founder of 10T Holdings and DTAP Capital, these are not isolated policy decisions—they reflect a system under pressure.
"I LOVE TARIFFS," Hayes <a href="https://x.com/cryptohayes/status/1907961898777391323?s=46">wrote</a> on X on Friday, sharing a chart showing the widening gap between the U.S. current account and financial account balances. "Global imbalances will be corrected, and the pain papered over with printed money, which is good for $BTC."
The chart he referenced shows the long-term divergence between the U.S. current account balance, which has plunged deeper into deficit since the early 2000s, and the financial account balance, which has grown substantially—fueled by inflows of foreign capital. 
This pattern illustrates how the U.S. has increasingly relied on financing from abroad to fund its deficits, making the economy vulnerable to shifts in global capital flows.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44638067/anthony-pompliano-praises-trumps-tariffs-as-catalyst-for-crypto-innovation">Anthony Pompliano Praises Trump&#8217;s Tariffs As Catalyst For Crypto Innovation</a>
Tapiero <a href="https://x.com/dtapcap/status/1908031555290935666?s=46">echoed</a> the sentiment, writing: "Tariffs represent battle ongoing in the old analog world… Bitcoin stands outside this world. Free of legacy burdens."
He framed tariffs as a reactionary tool, attempting to fix long-standing problems with outdated mechanisms: "In an attempt to solve old problems—excess government spending, FX manipulation, weak growth, geopolitics—so much manipulation and interference."
While mainstream financial markets have viewed tariffs through the lens of trade friction and inflationary risk, Hayes and Tapiero suggest the deeper takeaway is the fragility of a global economic system sustained by imbalances that cannot be resolved by conventional tools. 
In their view, <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44631522/bitcoin-as-trump-tariff-safe-haven-not-yet-but-might-decouple-over-time-expert-says">Bitcoin represents an exit from that paradigm</a>.
The endorsement of Bitcoin as a hedge against systemic risk fits into a broader narrative gaining traction among macro investors: that digital assets, especially Bitcoin, may be best understood not just as speculative instruments, but as structural alternatives to a weakening fiat-based system.
As the U.S. trade and fiscal picture deteriorates, with the current account deficit nearing historic lows, some investors see BTC as a potential long-term beneficiary—particularly if rising tariffs lead to currency devaluations and renewed money printing to offset economic shocks.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44631522/bitcoin-as-trump-tariff-safe-haven-not-yet-but-might-decouple-over-time-expert-says">Bitcoin As Trump Tariff Safe Haven? Not Yet, But &#8216;Might Decouple Over Time,&#8217; Expert Says</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Will Benefit From Tariff Chaos, Arthur Hayes Says

Management

AFRI

Forafric Global Names CEO Khalid Assari As Chairman Of Board, Effective April 4, 2025, Replacing Saad Bendidi

Tradeweb Reports Record $59.6T March Trading Volume, ADV Jumps 49.9% YoY to $2.71T

Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) shares are trading lower premarket on Friday. The oil giant anticipates changes in oil prices to add first-quarter Upstream earnings&nbsp;quarter-over-quarter&nbsp;<a target="_blank" href="https://www.benzinga.com/secfilings/25/04/44636947/exxon-mobil-corp-general-corporate-statement-form8-0000034088-25-000017" rel="noreferrer noopener">by&nbsp;</a>$0.0&nbsp;billion to&nbsp;$0.4 billion.
Also, changes in gas prices are expected to add to its Upstream results by $0.0&nbsp;billion&nbsp;and&nbsp;$0.4 billion compared to the fourth quarter.
Also, Exxon Mobil projects that variations in industry margins will positively impact Energy Products <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">earnings by&nbsp;$0.3 billion –&nbsp;$0.7 billion</a>.
On the other hand, the company expects change in industry margins to impact Chemical Products earnings by&nbsp;$(0.1)&nbsp;billion –&nbsp;$0.1 billion and Specialty Products earnings by&nbsp;$(0.3)&nbsp;billion –&nbsp;$(0.1)&nbsp;billion.
Moreover, changes in timing effects are expected to positively impact both Upstream and Energy Products earnings by $0.1 billion – $0.5 billion each.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/global/25/03/44477467/trumps-tariffs-on-buyers-of-venezuelan-oil-could-boost-energy-sector-exxon-mobil-stock" rel="noreferrer noopener">Trump&#8217;s Tariffs On Buyers Of Venezuelan Oil Could Boost Energy Sector, Exxon Mobil Stock</a>
Apart from this, changes in scheduled maintenance are projected to affect Upstream results by $0.0 billion –&nbsp;$0.2 billion, Energy Products by $(0.3) billion –&nbsp;$(0.1) billion, Chemical Products by $(0.1) billion –&nbsp;$0.1 billion and Specialty Products by $(0.1) billion –&nbsp;$0.1 billion.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/dashboard" rel="noreferrer noopener">Benzinga Pro</a>, analysts estimate Exxon Mobil to report&nbsp;first -quarter adjusted earnings per share of&nbsp;$1.70 and revenues of&nbsp;$86.09 billion.
Last month, the company disclosed that it is preparing to increase its isopropyl alcohol (IPA)&nbsp;production, aiming to produce 99.999% ultra-pure IPA to meet the <a target="_blank" href="https://www.benzinga.com/markets/equities/25/03/44497833/exxon-mobil-eyes-semiconductor-boom-with-99-999-pure-isopropyl-alcohol-production-expansion-details" rel="noreferrer noopener">growing needs of the semiconductor sector</a>.
Exxon's Baton Rouge facility will undergo upgrades to manufacture this high-purity IPA to meet the growing demand by 2027.
Investors can gain exposure to XOM via&nbsp;THOR Equal Weight Low Volatility ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THLV#NYSE">THLV</a>) and ALPS Equal Sector Weight ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQL#NYSE">EQL</a>).
Price Action: XOM shares are down 3.53% at $108.46 premarket at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44560678/chevron-exxon-hess-lead-as-tech-giants-stumble-in-q1-2025" target="_blank" rel="noreferrer noopener">Chevron, Exxon, Hess Lead As Tech Giants Stumble In Q1 2025</a></li>
</ul>
Image via Shutterstock.

Equities

Large Cap

Guidance

Movers

THOR Financial Technologies Trust THOR Low Volatility ETF

THLV

Exxon Mobil Projects Sequential Earnings Bump On Energy Price Swings Ahead Of Q1 Report

American Shared Hospital (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMS#AMEX">AMS</a>) reported quarterly losses of $(0.20) per share. This is a 433.33 percent decrease over earnings of $0.06 per share from the same period last year. The company reported $9.07 million in sales this quarter. This is a 59.16 percent increase over sales of $5.70 million the same period last year.

Earnings

American Shared Hospital Q4 2024 GAAP EPS $(0.20) Down From $0.06 YoY, Sales $9.07M Up From $5.70M YoY

NGVC

Natural Grocers Launches Three New Non-GMO Peruvian Chip Varieties Under Store Brand

Health Care

General

American Shared Hospital Services Appoints Gary Delanois As CEO

"This transaction will strengthen the company's investment grade balance sheet by reducing our borrowings and unlocking the unrecognized value of critical assets," said Glenn Brandt, Chief Financial Officer. "With this transaction, Rogers will have issued an aggregate $9 billion of equity-valued capital since year-end, which is expected to reduce leverage by almost 1 turn."

Rogers to Use C$7B Investment From Blackstone-Led Group To Repay Debt And Boost Balance Sheet

The Greenbrier Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBX#NYSE">GBX</a>) will release earnings results for the second quarter, after the <a href="https://www.benzinga.com/quote/GBX/earnings">closing bell on Monday, April 7.</a>
Analysts expect the Lake Oswego, Oregon-based company to report quarterly earnings at $1.78 per share, up from $1.03 per share in the year-ago period. Greenbrier projects to report quarterly revenue at $898.53 million, compared to $862.7 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Thursday, Greenbrier announced a 7% increase to its quarterly dividend.
Greenbrier shares tumbled 9.4% to close at $47.10 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/GBX/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>B of A Securities analyst Ken Hoexter maintained an Underperform rating and raised the price target from $60 to $62 on Jan. 9, 2025. This analyst has an accuracy rate of 64%.</li>
<li>Stephens &amp; Co. analyst Justin Long maintained an Overweight rating and increased the price target from $62 to $65 on April 8, 2024. This analyst has an accuracy rate of 70%.</li>
</ul>
Considering buying GBX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="591" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04031446/image-1-10-1024x591.png" alt="" class="wp-image-856981" style="width:553px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04031446/image-1-10-1024x591.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04031446/image-1-10-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04031446/image-1-10-768x443.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04031446/image-1-10.png 1113w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44626468/top-3-risk-off-stocks-that-are-ticking-portfolio-bombs">Top 3 Risk Off Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Markets

Trading Ideas

Greenbrier Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Under the terms of the transaction, Blackstone will acquire a non-controlling interest in a new Canadian subsidiary of Rogers that will own a minor part of Rogers wireless network.&nbsp;Rogers will maintain full operational control of its network and will include the financial results of the subsidiary in its consolidated financial statements.
 &nbsp;

Rogers Communications Inks C$7B Deal With Blackstone, CPP And Others for 49.9% Stake In New Wireless Subsidiary

D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>) with a Buy and maintains $22 price target.

RCEL

D. Boral Capital Maintains Buy on AVITA Medical, Maintains $22 Price Target

EQUINIX REVERSES EARLY WEAKNESS AFTER ALERT ON NEGATIVE DAY FOR BROAD MARKET
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/03201757/Screenshot-2025-04-03-at-4.14.47%E2%80%AFPM-1007x1024.png" alt="" class="wp-image-9720" /></figure>
Equinix, Inc. (EQIX) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 10:08 AM on April 3rd, a significant trading signal occurred for Equinix, Inc. (EQIX) as it demonstrated a Power Inflow at a price of $789.95. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Equinix&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Equinix&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for EQIX, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; &nbsp; <a href="https://www.tradepulse.net">https://www.tradepulse.net</a>&nbsp; which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:The price at the time of the Power Inflow was $789.95. The returns on the high price post-signal ($809.36) and close price ($801.44) after the Power Inflow are respectively 2.5% and 1.5%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.
Past Performance Not Indicative of Future Results

WIIM

Technicals

Signals

Equinix Stock Up 2.5% After key Signal, Despite Market Sell-off

The Company expects to receive aggregate gross proceeds of US$9.8 million from the Offering, before deducting underwriting discounts and other related expenses.

IPOs

BLIV

BeLive Holdings Prices IPO Of 2.45M Ordinary Shares At $4.00 Per Share; Shares Expected To Commence Trading On April 4, Under Ticker Symbol 'BLIV'

American Shared Hospital Services Q4 Revenue Rises 59.2% YoY To $9.069M, Exits Quarter With Cash And Equivalents Worth $11.275M

Needham analyst Scott Berg reiterates Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Buy and maintains $52 price target.

FIVN

Needham Reiterates Buy on Five9, Maintains $52 Price Target

Rosenblatt analyst Catharine Trebnick maintains Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Buy and maintains $58 price target.

Rosenblatt Maintains Buy on Five9, Maintains $58 Price Target

Top billionaires Elon Musk, Mark Zuckerberg, and Jensen Huang lost nearly $34 billion after the bloodbath on Wall Street on Thursday. Here&#8217;s how much the &#8216;Magnificent 7&#8217; billionaires lost in total.
What Happened: Wall Street witnessed its most brutal trading day in years, with all major U.S. stock indexes experiencing their largest single-day drops on Thursday since the COVID-19 pandemic.
The richest business leaders lost billions of dollars as the stock market declined. Notably, Meta Platforms Inc.&#8216;s founder, chairman, and CEO, Zuckerberg, lost $17.9 billion in a single day, according to Forbes data.
Amazon.com Inc. founder Jeff Bezos saw his net worth plummet by a staggering $16 billion, while Tesla Inc. co-founder and CEO Musk lost $8.7 billion amid the market selloff.
On the other hand, chipmaker Nvidia Corp.&#8216;s founder and CEO, Huang, saw a $7.4 billion change in his net worth, whereas Microsoft Corp. co-founder Bill Gates&#8216; wealth tumbled by $774 million on Thursday.
Alphabet Inc. co-founders Larry Page and Sergey Brin lost $4.9 billion and $4.6 billion, respectively, while the company&#8217;s CEO, Sundar Pichai, saw his net worth decline by $18 million.
Apple Inc. CEO Tim Cook witnessed a loss of $68 million.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Stocks</td>
<td>YTD Performance</td>
<td>Thursday&#8217;s Performance</td>
<td>Business Leaders</td>
<td>Change In Wealth (In Billion Dollars)</td>
</tr>
<tr>
<td>Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>-26.40%</td>
<td>-7.81%</td>
<td>Jensen Huang</td>
<td>-7.4</td>
</tr>
<tr>
<td>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</td>
<td>-16.67%</td>
<td>-9.25%</td>
<td>Tim Cook</td>
<td>-0.068</td>
</tr>
<tr>
<td>Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</td>
<td>-10.86%</td>
<td>-2.36%</td>
<td>Bill Gates</td>
<td>-0.774</td>
</tr>
<tr>
<td>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>-18.99%</td>
<td>-8.98%</td>
<td>Jeff Bezos</td>
<td>-16</td>
</tr>
<tr>
<td>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)</td>
<td>-19.93%</td>
<td>-3.92%</td>
<td>Sundar Pichai</td>
<td>-0.018</td>
</tr>
<tr>
<td>Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</td>
<td>-11.28%</td>
<td>-8.96%</td>
<td>Mark Zuckerberg</td>
<td>-17.9</td>
</tr>
<tr>
<td>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</td>
<td>-5.47%</td>
<td>-29.53%</td>
<td>Elon Musk</td>
<td>-8.7</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Source: Forbes</figcaption></figure>
See Also: <a href="https://www.benzinga.com/general/market-summary/25/04/44643368/donald-trump-says-market-is-going-to-boom-claiming-6-7-trillion-worth-of-inflows-will-come">Donald Trump Says &#8216;Market Is Going To Boom,&#8217; Claiming &#8216;$6-7 Trillion&#8217; Worth Of Inflows Will Come After The Worst Selloff Since 2020</a>
Why It Matters: The Dow Jones endured its fifth-worst day in history, shedding 1,679 points. It was Dow and S&amp;P 500&#8217;s worst trading day since June 2020. Meanwhile, the Nasdaq had its most significant single-day decline since March 2020.
Citing the necessity to rectify the United States' trade deficit, Trump utilized a 1977 statute to officially declare a trade emergency, subsequently introducing new tariffs on Wednesday.
He imposed a blanket 10% tariff on all trading partners and levied more duties on the countries he described as "bad actors".
It is worth noting that China, Vietnam, Cambodia, and Sri Lanka are subject to the most severe tariffs, whereas Canada and Mexico were exempted from &#8220;Liberation Day&#8221; tariffs.
Benchmark indices are in the correction zone. The S&amp;P 500 fell 12.22% from its Feb. 19th peak, the Nasdaq 100 dropped 16.65% from its 52-week high, approaching the bear market territory, and the Dow was down 10.05% as of Thursday.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, declined in premarket on Friday. The SPY was down 2.30% to $525.78, while the QQQ declined 2.52% to $439.32, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44642131/volatility-gauge-vix-surges-to-an-8-month-high-more-fear-more-opportunity-says-analyst" target="_blank" rel="noreferrer noopener">Volatility Gauge Vix Surges To An 8-Month High: ‘More Fear Equals More Opportunity,' Says Analyst</a></li>
</ul>
Image via Shutterstock

Tech

AAPL

AMZN

GOOG

GOOGL

MSFT

NVDA

TSLA

Elon Musk, Mark Zuckerberg And Jensen Huang See $34 Billion Wiped Out In A Single Day: Here's How Much Other 'Magnificent 7' Billionaires Lost After Trump's Liberation Day

IREN

IREN March 2025 Bitcoin Mined 533 BTC, Up From 459 BTC In Feb; Revenue $45.3M, Up From $43.9M In Feb

Press Releases

Scilex Holding Company Announces that It Will Be Filing Today of a Supplemental New Drug Application with the FDA for ELYXYB® in Acute Pain Indication

Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC

Contracts

Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025

Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)

Scilex Holding Company Announces that the U.S. FDA Has Acknowledged the Submission of Our Supplemental New Drug Application for ELYXYB® in Acute Pain Indication

Dividends

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025

Legal

Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva

DECA

SCLX

SRNE

ALT5 Sigma

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Alto Neuroscience

AN2 Therapeutics

Assertio Holdings

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Context Therapeutics

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Ikena Oncology

Opus Genetics

Iterum Therapeutics

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals

NRX Pharmaceuticals

Nutriband

Pliant Therapeutics

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Cassava Sciences

SCYNEXIS

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

Veru

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

Ventyx Biosciences

D. Boral Capital

HC Wainwright & Co.

Alliance Global Partners

Rodman & Renshaw

B. Riley Securities

Semnur Pharmaceuticals, Inc., A Wholly Owned Subsidiary Of Scilex Holding Company, Announces Today The Filing Of A Registration Statement On Form S-4 by Denali Capital Acquisition Corp. With The Securities And Exchange Commission Relating To The Previously Announced Proposed Business Combination Between Semnur And Denali

Skyscrapers,Cityscape,Downtown,View,,Nashville,Skyline,Buildings.,Beautiful,Real,Estate.

Scilex Holding Company Announces Signing Of A $50 Million Registered Convertible Financing To Refinance And Restructure Existing Debt &amp; Further Strengthens Financial Profile

United,States,Bankruptcy,Court,Sign

Biotech

SRNEQ

Scilex Holding Company Announces That The U.S. Bankruptcy Court Has Extended The Lockup Period On Shares Of Scilex Dividend Stock Previously Distributed By Sorrento To Its Stockholders As A Dividend To January 31, 2025

Business,Analyst,Checking,In,Financial,Statement,For,Audit,Internal,Control

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended July 31, 2024

Hand,Of,Human,Holding,Crystal,Globe,Ball,With,Tree,For

Scilex Holding Company Announces Publication of Its Inaugural Sustainability Report

Business,Man,Sign,A,Contract,Investment,Professional,Document,Agreement.,Meeting

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination

Businessmen,Making,Handshake,With,Partner,,Greeting,,Dealing,,Merger,And,Acquisition,

Scilex Holding Company Partners With New National Distributor, Endeavor Distribution LLC.

Muscular,Man,Suffering,From,Back,And,Neck,Pain.,Incorrect,Sitting

Scilex Holding Company Announces Publication In PAIN Journal Regarding Phase 3 Results Of The Pivotal Registration Trial Of SP-102 (SEMDEXA™) In Lumbosacral Radicular Pain (Sciatica)

Outside,Of,Logistics,Warehouse,With,Open,Door,,Delivery,Van,Loaded

Scilex Holding Company Announces That Many National Pharmacy Chains And Independent Pharmacies Have Begun Stocking GLOPERBA®

Interior,Of,A,Modern,Warehouse,Storage,Of,Retail,Shop,With

Scilex Holding Company Announces Stocking Of GLOPERBA® Is Underway In All Of The Wholesalers With Which Scilex Has Stocking Arrangements Throughout The U.S.

Comments

Scilex Holding

Scilex Holding (SCLX) Opciones

Scilex Holding (NASDAQ:SCLX) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL